Clinical trials: Zoster Varicella
Varicella-zoster Virus
Phase III Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the vaccine efficacy, safety and immunogenicity of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07817108
- Testing
- ABO1108
- Where
- 4 sites in China
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Herpes Zoster
Long-term Effectiveness of the Live Attenuated Herpes Zoster Vaccine
This is a multicenter retrospective cohort study to evaluate the long-term effectiveness of the live attenuated herpes zoster vaccine within 6 years after vaccination.
- Trial name
- NCT07585370
- Testing
- Attenuated Zoster Vaccine, Live
- Where
- China
- Volunteers
- 24,740 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Varicella-zoster Virus
Phase I Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the tolerability, reactogenicity and safety of 2 injections (approximately 2 months apart) of three different dose levels of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285265
- Testing
- ABO1108, SHINGRIX
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Varicella-zoster Virus
Phase II Clinical Trial of Lyophilized Herpes Zoster mRNA Vaccine in Adults Aged 40 Years or Above
The primary objective of this study is to evaluate the immunogenicity and safety of 2 injections (approximately 2 months apart) of ABO1108 in adults aged 40 years or above.
- Trial name
- NCT07285278
- Testing
- ABO1108
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Suzhou Abogen Biosciences Co., Ltd.
Varicella Zoster Virus Infection
VZV-specific Tissue Resident Memory T-cells After Shingrix Vaccination
To evaluate the effect of intramuscular RZV vaccine on VZV-specific skin TRM and circulating T-cells
- Trial name
- NCT04403139
- Testing
- Shingrix
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Washington
Herpes Zoster
A Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50 and 69 years of…
- Trial name
- NCT06375512
- Testing
- HZ Vaccine (IN001), Shingrix
- Where
- 3 sites in United States, Australia
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Herpes Zoster
A Phase 2 Study to Describe the Safety, Reactogenicity, and Immunogenicity of Herpes Zoster IN001 mRNA Vaccine (IN001) in Healthy Participants
The study will evaluate the safety, tolerability, and immunogenicity (your immune system's reaction) of 3 dose levels of the study vaccine called Herpes Zoster IN001 mRNA Vaccine (IN001) in healthy participants who are between 50…
- Trial name
- NCT07205796
- Testing
- HZ Vaccine (IN001), Shingrix
- Volunteers
- 480 people, healthy volunteers welcome
- Sponsor
- Shenzhen Shenxin Biotechnology Co., Ltd
Varicella Zoster Virus Infection, Herpes Zoster
Clinical Trial to Evaluate EuHZV in Healthy Adults Aged 50 to 69 Years
Phase 1 clinical trial to evaluate the safety of HZV-1 and HZV-2 vaccines in healthy adults aged 50 to 69 years who have voluntarily given written consent to participate in this study.
- Trial name
- NCT06409494
- Testing
- EuHZV, Shingrix
- Where
- South Korea
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- EuBiologics Co.,Ltd
Pneumonia, Influenza
ACTIVATE in Public Housing
This multilevel, multidisciplinary, theoretically based, culturally sensitive, community-engaged intervention sets out to mitigate uptake barriers and non-adherence to vaccination schedules as recommended by the CDC and increase…
- Conditions
- Pneumonia, Influenza, Varicella Zoster, Meningitis
- Trial name
- NCT06075732
- Testing
- Increasing Willingness and Uptake of Influenza, Pneumonia, Meningitis, HZV, and COVID-19 Vaccination
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Charles Drew University of Medicine and Science
Zoster, Zoster Varicella
Systems Biology of Zoster Vaccine
The purpose of the study is to better understand how the immune system responds to the new herpes zoster (shingles) vaccine (Shingrix®). The study will be looking at certain markers in the blood after vaccination with Shingrix®.
- Conditions
- Zoster, Zoster Varicella, Shingles, Chicken Pox
- Trial name
- NCT04047979
- Testing
- Shingrix®
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Emory University
Zoster Varicella, Vaccination; Infection
The Influence of Trained Immunity in COVID-19 Vaccinated Individuals
The concept of trained immunity defines the long-term functional reprogramming of innate immune cells, which is evoked by exogenous or endogenous insults and leads to an altered response towards a second challenge after return to…
- Trial name
- NCT05705180
- Testing
- recombinant adjuvanted zoster vaccine
- Where
- Germany
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Wuerzburg University Hospital
Varicella Zoster Virus Infection
An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years
The goal of this bridging study is to assess the safety and immunogenicity of BARYCELA inj. in healthy Vietnamese children aged between 12 months to 12 years. The main questions it aims to answer are: Safety of BARYCELA inj.
- Trial name
- NCT05664152
- Testing
- MG1111
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- GC Biopharma Corp
Herpes Zoster, Varicella Zoster
Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects
The purpose of this clinical trial is to evaluate the safety, tolerability, and immunogenicity of vaccine candidate CRV-101, investigational vaccine in healthy adult subjects in the United States.
- Trial name
- NCT03820414
- Testing
- CRV 101
- Where
- United States
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Curevo Inc
Varicella Zoster Virus Infection, Herpes Simplex Virus Infection
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
A new paediatric formulation (oral liquid) has been developed for flexible and accurate dosing of valacyclovir in children. To establish the bioavailability of this new formulation, healthy volunteers will be exposed to the new…
- Trial name
- VALID-I (NCT01689285)
- Testing
- valacyclovir tablet, valacyclovir oral solution
- Where
- Netherlands
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Varicella Zoster Virus Infection, Herpes Simplex Virus Infection
Palatability Testing of a New Paediatric Formulation of Valacyclovir
Palatability testing of a new paediatric formulation of valacyclovir in children 4-12 years of age and at least one of their parents.
- Trial name
- VALID-0 (NCT01682109)
- Testing
- Valacyclovir
- Where
- Netherlands
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Rheumatoid Arthritis, Varicella Zoster
Safety of Zostavax Vaccination in Rheumatoid Arthritis
Herpes Zoster (shingles) is caused by reactivation of latent varicella zoster virus (VZV) that usually occurs decades following initial exposure. The risk of developing shingles increases with age.
- Trial name
- NCT01506661
- Testing
- Zostavax (varicella zoster virus) vaccine
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Oklahoma Medical Research Foundation
Varicella, Herpes Zoster
A Study to Evaluate Long-term Impact of VARIVAX Among Children and Adolescents (V210-036)(COMPLETED)
The purpose of these continuing post-licensure studies is to evaluate the long-term effectiveness of VARIVAX® [Varicella Virus Vaccine Live (Oka/Merck)] and to assess the impact of the vaccine on the epidemiology of varicella and…
- Trial name
- NCT01077804
- Volunteers
- 7,585 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Varicella Zoster, Immunization; Infection
Safety Study of NBP608 in Healthy Adult Volunteers
Indication: Protection against varicella and herpes zoster Study Objectives Primary: Safety and tolerability assessment after single dose administration of NBP608 Secondary: immunogenicity assessment after single dose…
- Trial name
- NCT03121638
- Testing
- VARIVAX, ZOSTAVAX, NBP6081
- Where
- South Korea
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- SK Chemicals Co., Ltd.
Herpes Zoster, Varicella-zoster Vaccine
Safety, Tolerability, and Immunogenicity of a Booster Dose of Zoster Vaccine, Live (V211-029)
This study was conducted to obtain safety and immunogenicity data after a booster dose of Zoster Vaccine, Live administered ≥10 years following an initial dose.
- Trial name
- NCT01245751
- Testing
- Zoster Vaccine, Live
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Herpes Simplex Infections, Human Papillomavirus
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
- Conditions
- Herpes Simplex Infections, Human Papillomavirus, Epstein-Barr Virus Infections, Varicella-zoster Virus Infection
- Trial name
- NCT02715752
- Testing
- Gene-Eden-VIR/Novirin
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The Center for the Biology of Chronic Disease